Molecular Determinants of hERG Channel Block by Terfenadine and Cisapride

被引:89
作者
Kamiya, Kaichiro [1 ]
Niwa, Ryoko [1 ]
Morishima, Mikio [1 ]
Honjo, Haruo [1 ]
Sanguinetti, Michael C. [2 ,3 ]
机构
[1] Nagoya Univ, Dept Cardiovasc Res, Environm Med Res Inst, Nagoya, Aichi 4648601, Japan
[2] Univ Utah, Dept Physiol, Salt Lake City, UT 84112 USA
[3] Univ Utah, Nora Eccles Harrison Cardiovasc Res & Training In, Salt Lake City, UT 84112 USA
基金
日本学术振兴会;
关键词
hERG; long QT syndrome; oocyte; voltage clamp;
D O I
10.1254/jphs.08102FP
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
Block of cardiac hERG K(+) channels by the antihistamine terfenadine and the prokinetic agent cisapride is associated with prolonged ventricular repolarization and an increased risk of ventricular arrhythmia. Here, we used a site-directed mutagenesis approach to determine the molecular determinants of hERG block by terfenadine and cisapride. Wild-type and mutant hERG channels were heterologously expressed in Xenopus laevis oocytes and characterized by measuring whole cell currents with two-microelectrode voltage clamp techniques. Mutation of T623, S624, Y652, or F656 to Ala reduced channel sensitivity to block by terfenadine. The same mutations reduced sensitivity to cisapride. These data confirm our previous findings that polar residues (T623, S624) located near the base of the pore helix and aromatic residues (Y652, F656) located in the S6 domain are key molecular determinants of the hERG drug binding site. Unlike methanesulfonanilides (dofetilide, MK-499, E-4031, ibutilide) or clofilium, mutation of V625, G648, or V659 did not alter the sensitivity of hERG channels to terfenadine or cisapride. As previously proposed by molecular modeling studies (Farid R, et al. Bioorg Med Chem. 2006;14:3160-3173), our findings suggest that different drugs can adopt distinct modes of binding to the central cavity of hERG.
引用
收藏
页码:301 / 307
页数:7
相关论文
共 33 条
[2]
Validation of a [3H]astemizole binding assay in HEK293 cells expressing HERG K+ channels [J].
Chiu, PJS ;
Marcoe, KF ;
Bounds, SE ;
Lin, CH ;
Feng, JJ ;
Lin, A ;
Cheng, FC ;
Crumb, WJ ;
Mitchell, R .
JOURNAL OF PHARMACOLOGICAL SCIENCES, 2004, 95 (03) :311-319
[3]
A MOLECULAR-BASIS FOR CARDIAC-ARRHYTHMIA - HERG MUTATIONS CAUSE LONG QT SYNDROME [J].
CURRAN, ME ;
SPLAWSKI, I ;
TIMOTHY, KW ;
VINCENT, GM ;
GREEN, ED ;
KEATING, MT .
CELL, 1995, 80 (05) :795-803
[4]
Diaz Gilbert J., 2004, Journal of Pharmacological and Toxicological Methods, V50, P187, DOI 10.1016/j.vascn.2004.04.001
[5]
New insights about HERG blockade obtained from protein modeling, potential energy mapping, and docking studies [J].
Farid, R ;
Day, T ;
Friesner, RA ;
Pearlstein, RA .
BIOORGANIC & MEDICINAL CHEMISTRY, 2006, 14 (09) :3160-3173
[6]
Physicochemical features of the hERG channel drug binding site [J].
Fernandez, D ;
Ghanta, A ;
Kauffman, GW ;
Sanguinetti, MC .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (11) :10120-10127
[7]
Molecular determinants of inactivation and dofetilide block in ether a-go-go (EAG) channels and EAG-related K+ channels [J].
Ficker, E ;
Jarolimek, W ;
Brown, AM .
MOLECULAR PHARMACOLOGY, 2001, 60 (06) :1343-1348
[8]
[3H]dofetilide binding to HERG transfected membranes:: a potential high throughput preclinical screen [J].
Finlayson, K ;
Turnbull, L ;
January, CT ;
Sharkey, J ;
Kelly, JS .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2001, 430 (01) :147-148
[9]
Molecular determinants of cocaine block of human ether-a-go-go-related gene potassium channels [J].
Guo, J ;
Gang, HY ;
Zhang, ST .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2006, 317 (02) :865-874
[10]
MUTATIONS IN THE K+ CHANNEL SIGNATURE SEQUENCE [J].
HEGINBOTHAM, L ;
LU, Z ;
ABRAMSON, T ;
MACKINNON, R .
BIOPHYSICAL JOURNAL, 1994, 66 (04) :1061-1067